Dmitry Balyasny’s PDS Biotechnology PDSB Stock Holding History

Dmitry Balyasny’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,802	Closed	-$128K	–	2755
2021 Q4	$128K	Buy	+15,802	New	+$170K	﹤0.01%	1929

Other funds holding PDSB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Dmitry Balyasny's PDSB Position: Q1 2022 in Review

Dmitry Balyasny sold out of PDS Biotechnology (PDSB) in Q1 2022, closing a stake of 15,802 shares — an estimated $128K sold.

Dmitry Balyasny first reported a position in PDSB in Q4 2021 and held it in 1 quarter. The position peaked at $128K in Q4 2021. 52 funds tracked by Wall St. Rank hold PDSB as of Q1 2022.

Dmitry Balyasny reported no remaining PDS Biotechnology position as of Q1 2022 after selling out during the quarter.
Dmitry Balyasny sold 15,802 PDS Biotechnology shares in Q1 2022, an estimated $128K.
Dmitry Balyasny first reported a position in PDS Biotechnology in Q4 2021 and held it in 1 quarter.
Dmitry Balyasny's PDS Biotechnology position peaked at $128K in Q4 2021.
52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2022.

Based on Balyasny Asset Management's 13F filing for Q1 2022, filed 16 May 2022.